Abstract
Part I of this report appeared in the previous issue (Br. J. Cancer (1976) 34,585), and discussed the design of randomized clinical trials. Part II now describes efficient methods of analysis of randomized clinical trials in which we wish to compare the duration of survival (or the time until some other untoward event first occurs) among different groups of patients. It is intended to enable physicians without statistical training either to analyse such data themselves using life tables, the logrank test and retrospective stratification, or, when such analyses are presented, to appreciate them more critically, but the discussion may also be of interest to statisticians who have not yet specialized in clinical trial analyses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Peto, R., Pike, M., Armitage, P. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35, 1–39 (1977). https://doi.org/10.1038/bjc.1977.1
Issue Date:
DOI: https://doi.org/10.1038/bjc.1977.1
This article is cited by
-
Letrozole ovulation regimen for frozen-thawed embryo transfer in women with polycystic ovary syndrome: study protocol for a randomized controlled trial
Trials (2024)
-
Novel subgroups of obesity and their association with outcomes: a data-driven cluster analysis
BMC Public Health (2024)
-
Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232
Leukemia (2024)
-
Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I’M WOMAN)
Trials (2023)
-
Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis
Journal of Translational Medicine (2023)